厄达替尼价格多少？怎么购买？

The most common pathological type of urothelial carcinoma. A new drug (erdafitinib) for the treatment of adult urothelial cancer was jointly discovered by Astex Pharmaceuticals of the United States and Janssen Biotechnology, a subsidiary of Johnson & Johnson Pharmaceutical Group.

Erdafitinib, a new drug used to treat adult urothelial cancer, was jointly discovered by Astex Pharmaceuticals in the United States and Janssen Biotech, a subsidiary of the Johnson & Johnson Pharmaceutical Group, in June 2008. Astex Pharmaceuticals authorized Janssen Biotech's inhibitors that emerged from the FGFR research project for global licensing development and commercialization. As early as 2005, Astex Pharmaceuticals in the United States had collaborated with the UK Cancer Research Drug Discovery Group and Cancer Research Technology Co., Ltd. at the University of Newcastle (Newcastle) in the United Kingdom to start a research plan for FGFR inhibitors. In March 2018, the U.S. Food and Drug Administration (FDA) granted erdafitinib Breakthrough Therapy designation for the treatment of urothelial cancer.  

How much does erdafitinib cost? How to buy?

Medical Travel learned that Janssen is exported to Hong Kong in the specification of 4mg*28 tablets and the price is about $106,500. Patients who purchase erdafitinib exported to Hong Kong by Janssen need to purchase it through formal channels. One is to go to Hong Kong to buy it in person, ask a hospital doctor to write a prescription, and then take the medicine back to China for treatment. The second is to find domestic overseas medical service institutions (such as Medical Companion Travel), and let them translate the cases, express the medicines to the patients by direct mail, and also provide guidance and answer questions for the patients during the medication. This is currently the most economical and feasible solution.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: